Georgiamune

Introducing Georgiamune, a company reprogramming immune responses.

Georgiamune is developing first-in-class immunotherapies to restore immune system homeostasis in cancer and autoimmune diseases using dual-functioning antibodies and small molecules.

Loss of immune system homeostasis can lead to autoimmune diseases and cancer due to over-active or under-active immune responses.

Georgiamune has developed novel biologic platforms to re-program T cells, targeting specific epitopes and functional signaling pathways.

Georgiamune's pipeline includes pioneering therapeutics like dual-functioning antibodies and immune-reprogramming small molecules across various stages of development.

Our team of innovative and experienced leaders, advisors, and board members is spearheaded by industry veterans and supported by renowned figures in immunotherapy.

GIM-122 is a dual-functioning antibody that overcomes limitations of current checkpoint inhibitors by reversing resistance to immunotherapy and activating T cells.

While checkpoint inhibitors have changed cancer therapy, they are ineffective for many patients, necessitating a novel approach to overcome checkpoint resistance.

A strategic partnership with Verily enhances our ability to develop predictive and outcome biomarkers and drive efficient clinical development using advanced molecular data.

Our selective Treg inhibitors and activators, including GIM-531 for cancer and GIM-407 for autoimmune diseases, target regulatory T cells to reprogram immune responses effectively.

Tregs play a key role in cancer and autoimmune diseases. We address this by selectively inhibiting or activating Tregs to combat these diseases, presenting a significant market opportunity.

Current Treg therapies are not selective, leading to off-target effects. Our Treg-specific approach avoids these pitfalls, offering a competitive edge.

Autoimmune diseases affect over 24 million Americans. Our novel Treg activator targets these diseases at the source, offering a transformative therapeutic option.

Georgiamune is at the forefront of reprogramming immune responses to combat cancer and autoimmune diseases.